Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Share-based Compensation (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Share-based Compensation for 12 consecutive years, with $2.4 million as the latest value for Q1 2026.

  • For Q1 2026, Share-based Compensation fell 3.39% year-over-year to $2.4 million; the TTM value through Mar 2026 reached $10.4 million, up 36.26%, while the annual FY2025 figure was $10.5 million, 59.85% up from the prior year.
  • Share-based Compensation hit $2.4 million in Q1 2026 for Cartesian Therapeutics, up from $2.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $14.1 million in Q4 2023 and bottomed at $1.4 million in Q1 2024.
  • Average Share-based Compensation over 5 years is $3.1 million, with a median of $2.4 million recorded in 2026.
  • Year-over-year, Share-based Compensation skyrocketed 521.44% in 2023 and then crashed 86.81% in 2024.
  • Cartesian Therapeutics' Share-based Compensation stood at $2.3 million in 2022, then surged by 521.44% to $14.1 million in 2023, then plummeted by 86.81% to $1.9 million in 2024, then grew by 14.96% to $2.1 million in 2025, then increased by 13.01% to $2.4 million in 2026.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $2.4 million, $2.1 million, and $2.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.